Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries.
| Autor: | Turnak MR; Lilly Research Laboratories, Lilly Corporate Center, DC 6061, Indianapolis, IN 46285, USA. turnak_mark@lilly.com, Bandak SI, Bouchillon SK, Allen BS, Hoban DJ |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2001 Dec; Vol. 7 (12), pp. 671-7. |
| DOI: | 10.1046/j.1469-0691.2001.00344.x |
| Abstrakt: | Objective: To determine antimicrobial activity against Haemophilus influenzae and Moraxella catarrhalis. Methods: A central laboratory performed NCCLS susceptibility testing for all isolates and beta-lactamase and capsular serotype determinations for H. influenzae. Results: A total of 2712 H. influenzae and 1079 M. catarrhalis were collected. H. influenzae susceptibilities were >90% for amoxicillin/clavulanate, cefaclor, loracarbef, cefprozil, cefuroxime, ciprofloxacin, azithromycin and clarithromycin and were <80% for trimethoprim/sulfamethoxazole and ampicillin. 19.3% were beta-lactamase positive. The most common serotype was type-b (5.6%); 86.1% were nontypeable. M. catarrhalis had MIC90 within therapeutic range for all antimicrobials except ampicillin. Conclusion: The conclusion of the study is that antimicrobials, except ampicillin and trimethoprim/sulfamethoxazole, remain good empiric choices against H. influenzae and M. catarrhalis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|